Lumos Pharma, Inc. (NASDAQ:LUMO) Q1 2024 Earnings Call Transcript
Operator: Greetings, and welcome to Lumos Pharma First Quarter 2024 Financial Results and Clinical Programs Update Call. At this time, all participants are in a listen-only mode.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Leucadia National Ian Cumming And Joseph Steinberg | 120,651 | $340,236 | 0% | |
2. | Lion Point Didric Cederholm | 90,794 | $256,039 | 0.14% | |
3. | Millennium Management Israel Englander | 37,579 | $105,973 | 0% | |
4. | Two Sigma Advisors John Overdeck And David Siegel | 31,900 | $89,958 | +13% | 0% |
5. | Citadel Investment Group Ken Griffin | 13,286 | $37,467 | 0% |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 417,051 | $1,326,222 | 0% | |
2. | 406,611 | $1,293,023 | 0% | |
3. | 326,552 | $1,038,435 | 0% | |
4. | 244,082 | $776,181 | 0% | |
5. | 125,282 | $394,202 | 0.2% |